 | Up a level |
Janssen, J J W M; Löwenberg, B; Manz, M; Biemond, B J; Westerweel, P E; Klein, S K; Fehr, M; Sinnige, H A M; Efthymiou, A; Legdeur, M C J C; Pabst, T; Gregor, M; van der Poel, M W M; Deeren, D; Tick, L W; Jongen-Lavrencic, M; van Obbergh, F; Boersma, R S; de Weerdt, O; Chalandon, Y; ... (2022). Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Leukemia, 36(9), pp. 2189-2195. Nature Publishing Group 10.1038/s41375-022-01657-3
Ossenkoppele, G J; Breems, D A; Stuessi, G; van Norden, Y; Bargetzi, M; Biemond, B J; A von dem Borne, P; Chalandon, Y; Cloos, J; Deeren, D; Fehr, M; Gjertsen, B; Graux, C; Huls, G; Janssen, J J J W; Jaspers, A; Jongen-Lavrencic, M; de Jongh, E; Klein, S K; van der Klift, M; ... (2020). Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. Leukemia, 34(7), pp. 1751-1759. Nature Publishing Group 10.1038/s41375-020-0725-0
Cornelissen, J J; Versluis, J; Passweg, Jakob; van Putten, W L J; Manz, M G; Maertens, J; Beverloo, H B; Valk, P J M; van Marwijk Kooy, M; Wijermans, P W; Schaafsma, M R; Biemond, B J; Vekemans, M-C; Breems, D A; Verdonck, L F; Fey, Martin; Jongen-Lavrencic, M; Janssen, J J W M; Huls, G; Kuball, J; ... (2015). Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. Leukemia, 29(5), pp. 1041-1050. Nature Publishing Group 10.1038/leu.2014.332
